Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Menu
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
Oracle’s stock is rising. Why TikTok’s U.S. deal could be good news for the tech company.
FedEx calls for more profit this year as this key business turns around
Airfares fell more than 5% in November — but will the deals last?
Nike says turnaround plans are ‘in the middle innings,’ but investor worries remain
How investors can take advantage of a quirky midterm election cycle
When retirees go back to work is it a sign of a strong labor force — or a recession?
The stock market right now is poised for a breakout — or a breakup
Bonds are having their best year since 2020. But don’t expect the same returns next year.
Nvidia and other chip stocks rise — but the AI trade may not be back for good
Uber’s stock is almost historically cheap. Are robotaxis an existential threat?
OK, boomer: Why you should start giving your money to your adult kids now
CoreWeave and Nebius shares rebound. Were debt fears too extreme?
Oracle’s stock is rising. Why TikTok’s U.S. deal could be good news for the tech company.
FedEx calls for more profit this year as this key business turns around
Airfares fell more than 5% in November — but will the deals last?
Nike says turnaround plans are ‘in the middle innings,’ but investor worries remain
How investors can take advantage of a quirky midterm election cycle
When retirees go back to work is it a sign of a strong labor force — or a recession?
The stock market right now is poised for a breakout — or a breakup
Bonds are having their best year since 2020. But don’t expect the same returns next year.
Nvidia and other chip stocks rise — but the AI trade may not be back for good
Uber’s stock is almost historically cheap. Are robotaxis an existential threat?
OK, boomer: Why you should start giving your money to your adult kids now
CoreWeave and Nebius shares rebound. Were debt fears too extreme?
A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.
18-12-25
Eli Lilly and Novo Nordisk file their new weight-loss drugs with the FDA.
Share this on:
